Key result
Levosimendan improves symptoms and subpulmonary LV systolic function in ccTGA.
Why the study?
The effects of levosimendan on acute decompensated heart failure in patients with congenitally corrected transposition of the great arteries are not well characterized.
Case Report (n=1)
Answers are grounded in this paper and cite their sources.
May support levosimendan in select ccTGA cases; hypothesis-generating and requires prospective trials before practice change.
We present a case of acute decompensated heart failure in a patient with congenitally corrected transposition of great arteries treated with levosimendan, an agent with positive inotropic and vasodilatory effects. Levosimendan infusion resulted in symptomatic and functional improvement, improvement of the subpulmonary left ventricular systolic function and amelioration of the diastolic but not the systolic function of the systemic right ventricle. A number of factors may account for the poor response of the systemic right ventricle to levosimendan, such as altered myofibrillar structure and coronary flow together with the particular loading conditions of the systemic right ventricle.
No takes yet. Share an insight, caveat, or question.
Lilian Mantziari (2012) conducted a case report in Acute decompensated heart failure with congenitally corrected transposition of great arteries (n=1). Levosimendan was evaluated on Symptomatic and functional improvement, and ventricular function. Levosimendan infusion in a patient with congenitally corrected transposition of great arteries resulted in symptomatic improvement and improved subpulmonary left ventricular systolic function.
Synapse has enriched 10 related papers. Consider them for comparative context: